Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “CTOR”

756 pharma patents match "CTOR" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 756
Index total 30,257
Page 11 / 32

Quick answer

This filtered view shows 756 pharmaceutical patents matching "CTOR" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

756 results for “CTOR” · 30,257 patents in full index Clear search

  1. US 10596247

    Methods and compositions for attenuated chlamydia as vaccine and vector

    The Board of Regents of the University of Texas System · Granted Mar 24, 2020 · Expires Mar 19, 2040

    granted
  2. US 10588949

    Factor IX polypeptide formulations

    BIOVERATIV THERAPEUTICS INC. · Granted Mar 17, 2020 · Expires Mar 12, 2040

    granted
  3. US 10584356

    Multigenome retroviral vector preparations and methods and systems for producing and using same

    IMMUNE DESIGN CORP. · Granted Mar 10, 2020 · Expires Mar 5, 2040

    granted
  4. US 10584355

    Chimpanzee adenoviral vector-based filovirus vaccines

    The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services · Granted Mar 10, 2020 · Expires Mar 5, 2040

    granted
  5. US 10568943

    Factor IX polypeptides and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Feb 25, 2020 · Expires Feb 20, 2040

    granted
  6. US 10570214

    Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 25, 2020 · Expires Feb 20, 2040

    granted
  7. US 10564149

    Populations of mesenchymal stem cells that secrete neurotrophic factors

    BRAINSTORM CELL THERAPEUTICS LTD. · Granted Feb 18, 2020 · Expires Feb 13, 2040

    granted
  8. US 10561714

    Factor IX polypeptides and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Feb 18, 2020 · Expires Feb 13, 2040

    granted
  9. US 10562970

    Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Feb 18, 2020 · Expires Feb 13, 2040

    granted
  10. US 10548953

    Factor VIII-XTEN fusions and uses thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  11. US 10548954

    Factor IX polypeptides and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  12. US 10550164

    Brachyury deletion mutants, non-yeast vectors encoding Brachyury deletion mutants, and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  13. US 10543257

    Lentiviral vector for treating hemoglobin disorders

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 28, 2020 · Expires Jan 23, 2040

    granted
  14. US 10533053

    Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptor

    CytomX Therapeutics, Inc. · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted
  15. US 10525101

    Methods of treating inflammatory or autoimmune disorders with compounds that bind macrophage migration inhibitory factor

    United States Government as represented by the Department of Veterans Affairs · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  16. US 10513542

    Minicircle DNA vector vaccine platform for foot-and-mouth disease and methods thereof

    The Government of the United States of America, as represented by the Secretary of Homeland Security · Granted Dec 24, 2019 · Expires Dec 19, 2039

    granted
  17. US 10512675

    Adeno-associated virus factor VIII vectors, associated viral particles and therapeutic formulations comprising the same

    BIOMARIN PHARMACEUTICAL INC. · Granted Dec 24, 2019 · Expires Dec 19, 2039

    granted
  18. US 10501740

    Compositions and methods for inhibiting expression of factor V

    Alnylam Pharmaceuticals, Inc. · Granted Dec 10, 2019 · Expires Dec 5, 2039

    granted
  19. US 10494632

    Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Dec 3, 2019 · Expires Nov 28, 2039

    granted
  20. US 10463718

    Adeno-associated virus factor VIII vectors

    BIOMARIN PHARMACEUTICAL INC. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  21. US 10449232

    Puma protein expression vector and use thereof in gene therapy

    The Regents of the University of California · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted
  22. US 10450358

    Platelet-derived growth factor B mutant, preparation method therefor and use thereof

    Institute of Biotechnology, Academy of Military Medical Sciences, China · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted
  23. US 10434188

    Hyaluronic acid binding domain-growth factor fusion protein cDNAs and fusion proteins for cartilage matrix preservation and repair

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted
  24. US 10428132

    Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof

    WEST CHINA HOSPITAL, SICHUAN UNIVERSITY · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted